More than seventy doctors and international faculty participated in the two-day training workshop held in JSS medical college, Mysuru, Karnataka.
20th March 2023: Gufic Biosciences Limited (“Gufic”), a fast-growing pharmaceutical player, recognised for its innovative, high-quality pharmaceutical and herbal products organised a two-day mega cadaver workshop on Botulinum toxin and Dermal fillers. More than seventy doctors converged on a single platform and received training from an international faculty from Australia at this workshop held in JSS medical college, Mysuru.
Internationally renowned clinical experts explained the pertinent clinical facial anatomy to all the doctors and the delegates from pan-India. At the training programme, the experts laid emphasis on safe and reproducible techniques for the use of injectable HA dermal fillers and Botulinum toxin type A injections.
All the delegates were taken through holistic and extensive insights into the essential anatomy of the human face for safe practice in aesthetic medicine. The attending doctors and the healthcare professionals also witnessed the conclave on the real-time application of facial injectables with an emphasis on patient safety, efficacy and avoidance of structures in critical danger zones of the upper, middle and lower face.
Throwing light on the success of the Workshop, Mr. Rasik Kulkarni, Vice President, Gufic Biosciences Limited said, “Undoubtedly, the workshop played a crucial role in advancing the understanding of the emerging technologies and spreading new insights in this exclusive field. With a renewed sense of commitment, we aim to offer many such platforms for knowledge sharing in future as well.”
Gufic organised this course in association with the Cutis Academy and JSS Hospital Mysore. Meanwhile, the attending delegates at this workshop got a comprehensive understanding of various anatomical layers and structures within fresh embalming cadaver facial tissues. They also gained knowledge through the deliberations on how the facial injections influence volume loss and aging.
Mr Rasik Kulkarni VP Gufic Bioscience has expressed that Gufic has already gained abundant attention of the industry by launching the indigenously produced botulinum toxin type A injection called ‘Stunnox’ in the country. Stunnox has been developed and manufactured in collaboration with the US-based company, M/s. Prime Bio Inc.
